

【書籍】

No.	著者氏名	論文タイトル	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
1	尹浩信	全身性強皮症	渡辺晋一、古川福実	皮膚疾患最新の治療 2015-2016	南江堂	東京	2015	80-81
2	Kuwana M	Endothelial progenitor cells.	Takehara K, Fujimoto M, and Kuwana M	Systemic Sclerosis: Basic and Translational Research	Springer, London	UK	In press	
3	Kuwana M and Medsger TA, Jr	The clinical aspects of autoantibodies.	Varga J, Denton CP, Wigley FM, Allnore Y, and Kuwana M	Scleroderma –From Pathogenesis to Comprehensive Management	Springer, London	UK	In press	
4	Shah A and Kuwana M	Cancer in Systemic Sclerosis.	Varga J, Denton CP, Wigley FM, Allnore Y, and Kuwana M	Scleroderma –From Pathogenesis to Comprehensive Management	Springer, London	UK	In press	
5	桑名正隆	膠原病および類縁疾患に伴う肺病変	高橋和久、児玉裕三	EBM を活かす呼吸器診療	メジカルビュー社	東京	2015	319-324
6	白井悠一郎、桑名正隆	全身性強皮症の治療にステロイドを使ってよいのか？	川合眞一	実践に活かす！ステロイドのエビデンス	羊土社	東京	印刷中	
7	桑名正隆	膠原病に伴う肺高血圧症の診断と治療		診断と治療のABC104 肺高血圧症	最新医学社	大阪	2015	191-197
8	後藤大輔	6章 強皮症 大量の心嚢液貯留に対する治療は？	松本 功、保田晋助、三森経世、桑名正隆	リウマチ・膠原病診療ハイグレード 分子標的/Bio 時代のリウマチ・膠原病治	光文堂	東京	2015	255-256

				療ストラテジー				
9	Hasegawa M.	Biomarker.	Edited by Takehara K, Fujimoto M, Kuwana M.	Systemic Sclerosis:Recent Advance in Basic and Translational Research.	Springer • Japan.	Tokyo	in press	
10	長谷川 稔 .	強皮症の皮膚潰瘍にエンドセリン受容体拮抗薬は有用か?	宮地良樹	EBM 皮膚疾患の治療 up-to-date.	中外医学社	東京	2015	90-92
11	長谷川 稔 .	膠原病検査法	宮地良樹	定番 皮膚科外来検査のすべて	文光堂	東京	2015	102-105
12	波多野 将	強皮症に伴う肺高血圧症	小室一成, 佐地 勉, 坂田隆造	Annual Review 循環器 2015	中外医学社	東京	2015	188-194
13	波多野 将	肺高血圧症治療薬	小室一成, 候聡志, 渡辺昌文, 真鍋一郎, 波多野将	循環器内科ポケットバイブル	中山書店	東京	2015	494-501
14	波多野 将	プロスタグランジン製剤(内服・吸入・皮下注など)の作用機序と治療の実際, 今後の展開について教えてください	福田恵一	～早期診断・治療のための～肺高血圧症 Q&A	先端医学社	東京	2015	163-168
15	波多野 将	原発性肺高血圧症	秋澤忠男ら	医学大辞典	南山堂	東京	2015	732

16	藤本 学	皮膚硬化に対する評価と治療	松本功、保田晋助	リウマチ・膠原病診療ハイグレード 分子標的/Bio 時代のリウマチ・膠原病治療ストラテジー	文光堂	東京	2015	211-220
17	藤本 学	全身性強皮症	金澤一郎、永井良三	今日の診断指針 第7版	医学書院	東京	2015	1295-1297

【雑誌】

No	発表者氏名	論文タイトル	発表誌名	巻号	ページ	出版年
1	Wang Z, Jinnin M, Nakamura K, Harada M, Kudo H, Nakayama W, Inoue K, Nakashima T, Honda N, Fukushima S, Ihn H.	Long non-coding RNA TSIX is up-regulated in scleroderma dermal fibroblasts and controls collagen mRNA stabilization.	Exp Dermatol.	25(2)	131-6	2016
2	Nakamura K, Jinnin M, Kudo H, Inoue K, Nakayama W, Honda N, Kajihara I, Masuguchi S, Fukushima S, Ihn H.	The role of PSMB9 up-regulated by interferon signature in the pathophysiology of cutaneous lesions of dermatomyositis and lupus erythematosus.	J Dermatol.	Epub ahead of print		2015
3	Nakamura K, Nakatsuka N, Jinnin M, Makino T, Kajihara I, Makino K, Honda N, Inoue K, Fukushima S, Ihn H.	Serum concentrations of Flt-3 ligand in rheumatic diseases.	Biosci Trends.	9(5)	342-9	2015
4	Koga A, Kajihara I, Yamada S, Makino K, Ichihara A, Aoi J, Makino T, Fukushima S, Jinnin M, Ihn H.	Enhanced CCR9 expression levels in psoriatic skin are associated with poor clinical outcome to infliximab treatment.	J Dermatol.	Epub ahead of print		2015

5	Inoue M, Jinnin M, Wang Z, Nakamura K, Inoue K, Ichihara A, Moriya C, Sakai K, Fukushima S, Ihn H.	microRNA level is raised in the hair shafts of patients with dermatomyositis in comparison with normal subjects and patients with scleroderma.	Int J Dermatol.	Epub ahead of print		2015
6	Kudo H, Wang Z, Jinnin M, Nakayama W, Inoue K, Honda N, Nakashima T, Kajihara I, Makino K, Makino T, Fukushima S, Ihn H.	EBI3 Downregulation Contributes to Type I Collagen Overexpression in Scleroderma Skin.	J Immunol.	195(8)	3565-73	2015
7	Wang Z, Jinnin M, Kobayashi Y, Kudo H, Inoue K, Nakayama W, Honda N, Makino K, Kajihara I, Makino T, Fukushima S, Inagaki Y, Ihn H.	Mice overexpressing integrin α v in fibroblasts exhibit dermal thinning of the skin.	J Dermatol Sci.	79(3)	268-78	2015
8	神人正寿、尹 浩信	好酸球性筋膜炎の最近の考え方	皮膚病診療	38(1)	6-11	2016
9	江頭 翔、牧野貴充、藤澤明彦、神人正寿、尹 浩信	ガドリニウム造影剤投与から4年後に発症した腎性全身性線維症の1例	臨床皮膚	69	98-102	2015
10	尹 浩信	強皮症—発症から線維化にいたる病態について—	リウマチ科	53	239-243	2015
11	尹 浩信	リウマチ性疾患の診療ガイドライン・推奨・治療指針「全身性強皮症」	リウマチ科	54	283-286	2015
12	尹 浩信	全身性自己免疫難病の診断・重症度基準アップデート「全身性強皮症」	炎症と免疫	23	517-521	2015
13	Saigusa R, Asano Y, Taniguchi T, Yamashita T, Ichimura Y, Takahashi T, Toyama T, Yoshizaki A, Sugawara K, Tsuruta D,	Multifaceted contribution of the TLR4-activated IRF5 transcription factor in systemic sclerosis.	Proc Natl Acad Sci U S A.	112(49)	15136-41	2015

	Taniguchi T, Shinichi S.					
14	Toyama T, Asano Y, Akamata K, Noda S, Taniguchi T, Takahashi T, Ichimura Y, Shudo K, Sato S, Kadono T.	Tamibarotene ameliorates bleomycin-induced dermal fibrosis by modulating phenotypes of fibroblasts, endothelial cells, and immune cells.	J Invest Dermatol.	in press		
15	Yoshizaki A, Taniguchi T, Saigusa R, Fukasawa T, Ebata S, Numajiri H, Nakamura K, Yamashita T, Takahashi T, Toyama T, Asano Y, Tedder TF, Sato S.	Nucleosome in patients with systemic sclerosis: possible association with immunological abnormalities via abnormal activation of T and B cells.	Ann Rheum Dis.	Epub ahead of print		2015
16	Saigusa R, Asano Y, Yamashita T, Taniguchi T, Takahashi T, Ichimura Y, Toyama T, Yoshizaki A, Miyagaki T, Sugaya M, Sato S.	Fli1 deficiency contributes to the downregulation of endothelial protein C receptor in systemic sclerosis: a possible role in prothrombotic condition.	Br J Dermatol.	Epub ahead of print		2015
17	Ichimura Y, Asano Y, Akamata K, Noda S, Taniguchi T, Takahashi T, Toyama T, Tada Y, Sugaya M, Sato S, Kadono T.	Progranulin overproduction due to Fli-1 deficiency contributes to the resistance of dermal fibroblasts to tumor necrosis factor in systemic sclerosis.	Arthritis Rheumatol.	67(12)	3245-3255	2015
18	Wu CY, Asano Y, Taniguchi T, Sato S, Yu HS.	Serum level of circulating syndecan-1: A possible association with proliferative vasculopathy in systemic sclerosis.	J Dermatol.	42	1 - 4	2015

19	Wu CY, Asano Y, Taniguchi T, Sato S, Yu HS.	Serum heparanase levels: A protective marker against digital ulcers in patients with systemic sclerosis.	J Dermatol.	42	625-628	2015
20	Takahashi T, Asano Y, Noda S, Aozasa N, Akamata K, Taniguchi T, Ichimura Y, Toyama T, Sumida H, Kuwano Y, Tada Y, Sugaya M, Kadono T, Sato S.	A possible contribution of lipocalin-2 to the development of dermal fibrosis, pulmonary vascular involvement and renal dysfunction in systemic sclerosis.	Br J Dermatol.	173	681-689	2015
21	Miura S, Asano Y, Saigusa R, Yamashita T, Taniguchi T, Takahashi T, Ichimura Y, Toyama T, Tamaki Z, Tada Y, Sugaya M, Sato S, Kadono T.	Serum omentin levels: A possible contribution to vascular involvement in patients with systemic sclerosis.	J Dermatol.	42	461-466	2015
22	Saigusa R, Asano Y, Nakamura K, Miura S, Ichimura Y, Takahashi T, Toyama T, Taniguchi T, Noda S, Aozasa N, Akamata K, Sumida H, Miyazaki M, Tamaki Z, Yanaba K, Kuwano Y, Sato S.	Association of anti-RNA polymerase III antibody and malignancy in Japanese patients with systemic sclerosis.	J Dermatol.	42	524-527	2015
23	Miura S, Asano Y, Saigusa R, Yamashita T, Taniguchi T, Takahashi T, Ichimura Y, Toyama T, Tamaki Z, Tada Y, Sugaya M, Sato S, Kadono T.	Serum vaspin levels: A possible correlation with digital ulcers in patients with systemic sclerosis.	J Dermatol.	42	528-531	2015
24	Akamata K, Asano Y, Yamashita T, Noda S, Taniguchi T, Takahashi T, Ichimura Y, Toyama T, Trojanowska M, Sato S.	Endothelin receptor blockade ameliorates vascular fragility in endothelial cell-specific Fli-1-knockout mice by	Arthritis Rheumatol.	67 (5)	1335-1344	2015

		increasing Fli-1 DNA binding ability.				
25	Akamata K, Asano Y, Taniguchi T, Yamashita T, Saigusa R, Nakamura K, Noda S, Aozasa N, Toyama T, Takahashi T, Ichimura Y, Sumida H, Tada Y, Sugaya M, Kadono T, Sato S.	Increased expression of chemerin in endothelial cells due to Fli1 deficiency may contribute to the development of digital ulcers in systemic sclerosis.	Rheumatology (Oxford).	54	1308-1316	2015
26	Saigusa R, Asano Y, Taniguchi T, Yamashita T, Takahashi T, Ichimura Y, Toyama T, Tamaki Z, Tada Y, Sugaya M, Kadono T, Sato S.	A possible contribution of endothelial CCN1 downregulation due to Fli1 deficiency to the development of digital ulcers in systemic sclerosis.	Exp Dermatol.	24	127-132	2015
27	Taniguchi T, Asano Y, Akamata K, Noda S, Takahashi T, Ichimura Y, Toyama T, Trojanowska M, Sato S.	Fibrosis, vascular activation, and immune abnormalities resembling systemic sclerosis in bleomycin-treated Fli-1-haploinsufficient mice.	Arthritis Rheumatol.	67 (2)	517-526	2015
28	Takahashi T, Asano Y, Ichimura Y, Toyama T, Taniguchi T, Noda S, Akamata K, Tada Y, Sugaya M, Kadono T, Sato S.	Amelioration of tissue fibrosis by toll-like receptor 4 knockout in murine models of systemic sclerosis.	Arthritis Rheumatol.	67 (1)	254-265	2015
29	Motegi S, Yamada K, Toki S, Uchiyama A, Kubota Y, Nakamura T, Ishikawa O	Beneficial effect of botulinum toxin A on Raynaud's phenomenon in Japanese patients with systemic sclerosis: a prospective, case series	Journal of Dermatology	in press		

		study				
30	Uchiyama A, Yamada K, Perera B, Ogino S, Yokoyama Y, Takeuchi Y, Ishikawa O, Motegi S	Protective effect of botulinum toxin A after cutaneous ischemia-reperfusion injury	Scientific Reports	5	9072	2015
31	Motegi S, Toki S, Yamada K, Uchiyama A and Ishikawa O	Demographic and clinical features of systemic sclerosis patients with anti-RNA polymerase III antibodies.	Journal of Dermatology	42	189-92	2015
32	Uchiyama A, Yamada K, Buddhini P, Ogino S, Yokoyama Y, Takeuchi Y, Ishikawa O, Motegi S	Protective Effect of MFG-E8 After Cutaneous Ischemia-reperfusion Injury	Journal of Investigative Dermatology	135	1157-65	2015
33	Toki S, Motegi S, Yamada K, Uchiyama A, Kanai S, Yamanaka M, Ishikawa O	Clinical and laboratory features of systemic sclerosis complicated with localized scleroderma	Journal of Dermatology	42(3)	283-7	2015
34	Hattori M, Yokoyama Y, Hattori T, Motegi S, Amano H, Hatada I, Ishikawa O	Global DNA hypomethylation and hypoxia-induced expression of the ten eleven translocation (TET) family, TET1, in scleroderma fibroblasts	Experimental Dermatology	24(11)	841-6	2015
35	Higuchi T, Kawaguchi Y, Takagi K, Tochimoto A, Ota Y, Katsumata Y, Ichida H, Hanaoka M, Kawasumi H, Tochihara M, Yamanaka H	Sildenafil attenuates the fibrotic phenotype of skin fibroblasts in patients with systemic sclerosis.	Clin Immunol	161	333-338	2015
36	川口鎮司	膠原病に伴う間質性肺炎の治療	Medical Practice	32	1195-1199	2015

37	川口鎮司	強皮症分類基準	Rheumatol Clin Res	4	47-49	2015
38	川口鎮司	強皮症と特発性肺線維症に おける肺病変の相違	リウマチ科	54	85-89	2015
39	川口鎮司	膠原病性肺動脈性肺高血圧 症	Angiology Frontier	14	94-99	2015
40	Shima Y, Hosen N, Hirano T, Arimitsu J, Nishida S, Hagihara K, Narazaki M, Ogata A, Tanaka T, Kishimoto T, Kumanogoh A	Expansion of range of joint motion following treatment of systemic sclerosis with tocilizumab.	Modern Rheumatolog y	25(1)	134-7	2015
41	Hashimoto-Kataoka T, Hosen N, Sonobe T, Arita Y, Yasui T, Masaki T, Minami M, Inagaki T, Miyagawa S, Sawa Y, Murakami M, Kumanogoh A, Yamauchi-Takihara K, Okumura M, Kishimoto T, Komuro I, Shirai M, Sakata Y, Nakaoka Y	Interleukin-6/interleukin- 21 signaling axis is critical in the pathogenesis of pulmonary arterial hypertension	Proc Natl Acad Sci U S A	112(20)	E2677-86	2015
42	Yoshida Y, Ogata A, Kang S, Ebina K, Shi K, Nojima S, Kimura T, Ito D, Morimoto K, Nishide M, Hosokawa T, Hirano T, Shima Y, Narazaki M, Tsuboi H, Saeki Y, Tomita T, Tanaka T, Kumanogoh A	Semaphorin 4D Contributes to Rheumatoid Arthritis by Inducing Inflammatory Cytokine Production: Pathogenic and Therapeutic Implications	Arthritis Rheumatol	67(6)	1481-90	2015
43	Hamaguchi Y, Kodera M, Matsushita T, Usuda T, Kuwana M, Takehara K, and Fujimoto M	Clinical and immunological predictors of scleroderma renal crisis in Japanese systemic sclerosis patients with anti-RNA polymerase III antibodies.	Arthritis Rheumatol	67	1045-105 2	2015

44	Kimura M, Tamura Y, Takei M, Yamamoto T, One T, Kuwana M, Fukuda K, and Satoh T	Rapid initiation of intravenous epoprostenol infusion is the favored option in patients with advanced pulmonary arterial hypertension	PLoS One	10	e0121894	2015
45	Tamura Y, Kimura M, Takei M, Ono T, Kuwana M, Satoh T, Fukuda K, and Humbert M	Oral vasopressin receptor antagonist tolvaptan in right heart failure due to pulmonary hypertension	Eur. Respir. J	46	283-286	2015
46	桑名正隆	全身性強皮症	呼吸器内科	27	256-262	2015
47	桑名正隆	強皮症. 内科疾患の診断基準・病型分類・重症度	内科	115	1161-1163	2015
48	桑名正隆	強皮症	免疫性神経疾患 基礎・臨床研究の最新知見	73	655-660	2015
49	白井悠一郎、桑名正隆	腸管嚢胞状気腫症の病態・診断・治療	リウマチ科	53	431-435	2015
50	Kudo H, Wang Z, Jinnin M, Nakayama W, Inoue K, Honda N, Nakashima T, Kajihara I, Makino K, Makino T, Fukushima S, Ihn H	EBI3 Downregulation Contributes to Type I Collagen Overexpression in Scleroderma Skin.	J Immunol	195	3565-3573	2015
51	Wang Z, Jinnin M, Kobayashi Y, Kudo H, Inoue K, Nakayama W, Honda N, Makino K, Kajihara I, Makino T, Fukushima S, Inagaki Y, Ihn H	Mice overexpressing integrin α v in fibroblasts exhibit dermal thinning of the skin.	J Dermatol Sci	79	268-278	2015
52	Jinnin M	Recent progress in studies of miRNA and skin diseases.	J Dermatol	42(6)	551-558	2015

53	Washio M, Takahashi H, Kobashi G, Kiyohara C, Tada Y, Asami T, Ide Y, Atsumi T, Horiuchi T; Kyushu Sapporo SLE (KYSS) Study Group	Risk factors for development of systemic lupus erythematosus among Japanese females: medical history and reproductive factors.	Int J Rheum Dis	Epub ahead of print		
54	Ohshima K, Baba M, Tamai M, Yamamoto M, Ichinose K, Kishikawa N, Takahashi H, Kawakami A, Kuroda N	Immune complexome analysis of antigens in circulating immune complexes isolated from patients with IgG4-related dacryoadenitis and/or sialadenitis.	Mod Rheumatol	Epub ahead of print		
55	Matsushita T, Hamaguchi Y, Hasegawa M, Takehara K, Fujimoto M.	Decreased levels of regulatory B cells in patients with systemic sclerosis: association with autoantibody production and disease activity.	Rheumatology (Oxford).	55(2)	263-267	2016
56	Hamaguchi Y, Koder M, Matsushita T, Hasegawa M, Inaba Y, Usuda T, Kuwana M, Takehara K, Fujimoto M.	Clinical and immunologic predictors of scleroderma renal crisis in Japanese systemic sclerosis patients with anti-RNA polymerase III autoantibodies.	Arthritis Rheumatol.	Apr-67	1045-52	2015
57	Hasegawa M.	Biomarkers in systemic sclerosis: their potential to predict clinical courses.	J Dermatol.	43(1)	29-38	2016
58	Hasegawa M.	Use of dermoscopy in the evaluation of connective tissue diseases.	Dermatol Clin Res.	1(3)	41-48	2015
59	牧野 智、前田進太郎、松下貴史、濱口儒人、長谷川稔、藤本 学、竹原和彦	各種末梢循環改善薬を併用し完治し得た全身性強皮症に伴う難治性足趾壊疽の1例	皮膚科の臨床	57(1)	19-22	2015

60	長谷川 稔	皮膚から見た膠原病	アレルギー	64(1)	32-37	2015
61	Muraoka H, Imamura T, Hatano M, Maki H, Yao A, Kinugawa K, Komuro I.	Secure Combination Therapy With Low-Dose Bosentan and Ambrisentan to Treat Portopulmonary Hypertension Minimizing Each Adverse Effect.	Int Heart J	56	471-473	2015
62	Ko T, Hatano M, Nitta D, Muraoka H, Minatsuki S, Imamura T, Inaba T, Maki H, Yao A, Kinugawa K, Komuro I.	A case of interferon- α -induced pulmonary arterial hypertension after living donor liver transplantation.	Heart Vessels	In Press		
63	Fujino T, Yao A, Hatano M, Inaba T, Muraoka H, Minatsuki S, Imamura T, Maki H, Kinugawa K, Ono M, Nagai R, Komuro I.	Targeted therapy is required for management of pulmonary arterial hypertension after defect closure in adult patients with atrial septal defect and associated pulmonary arterial hypertension.	Int Heart J	56	86-93	2015
64	Minatsuki S, Miura I, Yao A, Abe H, Muraoka H, Tanaka M, Imamura T, Inaba T, Maki H, Hatano M, Kinugawa K, Yao T, Fukayama M, Nagai R, Komuro I	Platelet-derived growth factor receptor-tyrosine kinase inhibitor, imatinib, is effective for treating pulmonary hypertension induced by pulmonary tumor thrombotic microangiopathy.	Int Heart J	56	245-248	2015
65	Fukada I, Araki K, Minatsuki S, Fujino T, Hatano M, Numakura S, Abe H, Ushiku T, Iwase T, Ito Y.	Imatinib alleviated pulmonary hypertension caused by pulmonary tumor thrombotic microangiopathy in a patient with metastatic breast cancer.	Clin Breast Cancer		e167-170	2015

66	波多野 将	肺高血圧治療の新展開	月刊 Mebio	32	48-54	2015
67	波多野 将	右心機能に着目した肺高血圧症の治療戦略	CARDIAC PRACTICE	26	105-109	2015
68	波多野 将	PH の診断について	血栓と循環	23	218-224	2015
69	波多野 将	心臓移植レシipient候補患者における臓器障害の可逆性の評価	今日の移植	28	424-432	2015
70	波多野 将	リオシグアト（アデムパス®）	診断と治療	103	533-577	2015
71	波多野 将	その他の肺動脈性肺高血圧症	Medical Practice	32	1967-1970	2015
72	波多野 将	免疫抑制療法が有効であったオーバーラップ症候群の一例	Medical Practice	32	2038-2044	2015
73	波多野 将	強皮症に伴う肺高血圧症の診断と治療	呼吸と循環	63	1063-1072	2015
74	波多野 将	肺高血圧症に対する治療薬の使い方	診断と治療	103	725-731	2015
75	藤本 学	実地診療における膠原病関連自己抗体検査の使い方	MP メディカルプラクティス	32	1125-1129	2015
76	山本俊幸	Eosinophilic fasciitis with severe joint contracture in a patient with bladder cancer and B-cell lymphoma.	J Dermatol	43(1)	68 - 9	2016
77	山本俊幸	Paraneoplastic eosinophilic fasciitis with generalized morphea and vitiligo in a patient working with organic solvents.	J Dermatol	43	67-69	2016